DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

被引：3
|
作者：
Yoon, Jee Sun
Kim, Jin Won
Kim, Ji-Won
Kim, Tae-Yong
Nam, Ah-Rong
Bang, Ju-Hee
Seo, Hye-Rim
Kim, Jae-Min
Oh, Kyoung Seok
Mortimer, Peter G.
Smith, Simon
Oh, Do-Youn
机构：
[1] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea
[2] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Seongnam, South Korea
[3] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea
[4] AstraZeneca, R&D Oncol, Early Oncol Clin Sci, Cambridge, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.TPS4166
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4166
引用
收藏
页数：3
相关论文
共 50 条
  • [21] A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1
    Oh, Do-Youn
    He, Aiwu Ruth
    Qin, Shukui
    Chen, Li-Tzong
    Okusaka, Takuji
    Vogel, Arndt
    Kim, Jin Won
    Suksombooncharoen, Thatthan
    Lee, Myung Ah
    Kitano, Masayuki
    Burris, Howard A., III
    Bouattour, Mohamed
    Tanasanvimon, Suebpong
    Zaucha, Renata
    Avallone, Antonio
    Cundom, Juan
    Rokutanda, Nana
    Xiong, Julia
    Cohen, Gordon
    Valle, Juan W.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [22] Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
    Zhou, Nan
    Li, Xiaofen
    Yang, Yu
    Tan, Sirui
    Zhang, Shunyu
    Huang, Qiyue
    Gou, Hongfeng
    BMC CANCER, 2023, 23 (01)
  • [23] Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
    Nan Zhou
    Xiaofen Li
    Yu Yang
    Sirui Tan
    Shunyu Zhang
    Qiyue Huang
    Hongfeng Gou
    BMC Cancer, 23
  • [24] Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial (vol 16, pg 967, 2015)
    Valle, J. W.
    Wasan, H.
    Lopes, A.
    LANCET ONCOLOGY, 2015, 16 (09): : E427 - E427
  • [25] SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress)
    Bekaii-Saab, T.
    Kang, V.
    Walker, L.
    Nakamura, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S108 - S109
  • [26] SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: Biliary tract cancer cohort (trial in progress)
    Bekaii-Saab, T.
    Jin, F.
    Ramos, J.
    Tan, S.
    Nakamura, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S273 - S274
  • [27] A phase 2 study of BOLD-100 in combination with FOLFOX chemotherapy in patients with pretreated advanced biliary tract cancer: Efficacy and safety analysis (BOLD-100-001).
    O'Kane, Grainne M.
    Oh, Do-Youn
    Spratlin, Jennifer
    Rha, Sun Young
    Elimova, Elena
    Kavan, Petr
    Goodwin, Rachel Anne
    Cha, Yongjun
    Kim, Seung Tae
    McAllister, E. Russell
    Jones, Michelle
    Snow, Malcolm
    Lemmerick, Yasmin
    Spera, Gonzalo
    Pankovich, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer
    Chiang, N-J.
    Chen, L-T.
    Chen, J-S.
    Yang, S-H.
    Hsu, C.
    Shan, Y-S.
    Yen, C-J.
    Chen, M-H.
    Tsou, H-H.
    ANNALS OF ONCOLOGY, 2018, 29 : 50 - 50
  • [29] Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study (vol 7, pg 522, 2022)
    Oh, Do-Youn
    Lee, Kyung-Hun
    Lee, Dae-Won
    Yoon, Jeesun
    Kim, Tae-Yong
    Bang, Ju-Hee
    Nam, Ah-Rong
    Oh, Kyoung-Seok
    Kim, Jae-Min
    Lee, Young
    Guthrie, Violeta
    McCoon, Patricia
    Li, Weimin
    Wu, Song
    Zhang, Qu
    Rebelatto, Marlon C.
    Kim, Jin Won
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06): : E5 - E5
  • [30] A phase 1/2, first-in-human study of STX-478 monotherapy or in combination with fulvestrant in patients with breast cancer or other advanced solid tumors (trial in progress)
    Montero, Alberto
    Orr, Douglas
    Munster, Pamela
    LoRusso, Patricia
    Jhaveri, Komal
    Pluard, Timothy
    Winer, Ira
    Streit, Michael
    Patterson, Monica
    Roberts, Simon
    Corsi-Travali, Stefani
    Ewert, Courtney
    Juric, Dejan
    CANCER RESEARCH, 2024, 84 (09)
12345